oral glp-1 tablets BREAKING: The FDA has approved the first pill for obesity, marking a major milestone in the weight-loss drug market and a potential inflection point for treatment access. The daily pill Oral Wegovy® — First GLP-1

The patients and the ophthalmologists should work together with primary care physicians and endocrinologists to monitor patients on these medications, she adds

Importantly, patients who are alcohol dependent should not stop drinking suddenly without medical supervision, as this can lead to potentially dangerous withdrawal symptoms

10.1016/j.joca.2020.02.760

Limited access to GLP-1s in low-income and high-obesity regions threatens to widen existing health inequities, particularly in rates of diabetes, cardiovascular disease, and mobility-related conditions

Yes, SGLT2 inhibitors should be temporarily discontinued 3 days before major surgical procedures requiring fasting and during acute illness, particularly if experiencing reduced food intake, dehydration, or persistent vomiting

Indeed, continuous exenatide exposure once weekly elicited a greater response than did short-acting exenatide, improving glycemic and lipids controls and lipoprotein metabolism, and decreasing systemic inflammation